KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) FCF Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed FCF Margin for 11 consecutive years, with 822.6% as the latest value for Q1 2025.

  • On a quarterly basis, FCF Margin changed N/A to 822.6% in Q1 2025 year-over-year; TTM through Dec 2025 was 3732.23%, a N/A change, with the full-year FY2025 number at 3732.23%, changed N/A from a year prior.
  • FCF Margin was 822.6% for Q1 2025 at Xenon Pharmaceuticals, up from 23324.24% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 212.64% in Q1 2022 to a low of 23324.24% in Q3 2022.
  • A 3-year average of 3703.67% and a median of 599.26% in 2021 define the central range for FCF Margin.
  • Biggest YoY gain for FCF Margin was 27180bps in 2022; the steepest drop was -2298580bps in 2022.
  • Xenon Pharmaceuticals' FCF Margin stood at 567.94% in 2021, then plummeted by -4007bps to 23324.24% in 2022, then skyrocketed by 96bps to 822.6% in 2025.
  • Per Business Quant, the three most recent readings for XENE's FCF Margin are 822.6% (Q1 2025), 23324.24% (Q3 2022), and 3248.51% (Q2 2022).